Recent changes
- Oct 13, 2026Oct 13, 2026IPO $116.7M FinancialContent
- Oct 13, 2026Oct 13, 2026TRexBio Closes $116.7M IPO, Lilly Eyes Bigger Stake Pulse story
Funding History
1 event · sources dated per row| Date | Event | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| Oct 13, 2026 | ipo | $116.7M | — | FinancialContent |
Latest Pulse
- Oct 13, 2026The IPO Window: Biotech Keeps Pricing, Tech Still WaitsSmall biotech IPOs keep clearing the market while bigger, capital-intensive listings stall: City Therapeutics, TRexBio and Iambic all moved this week while Firmus's $31 billion listing sits withdrawn.→
- Oct 13, 2026TRexBio Closes $116.7M IPO, Lilly Eyes Bigger StakeTRexBio closed its IPO on Oct. 13, selling 8.33 million shares at $14 for about $116.7 million, with largest shareholder Eli Lilly signaling interest in raising its stake.→
- Oct 13, 2026Retension's $45M IPO Window Closes On ScheduleRetension Pharmaceuticals' upsized $45 million IPO was expected to close on or about Oct. 13, days after the hypertension-drug developer's shares began trading on Nasdaq.→
Coverage Timeline
newest firstAll Coverage
IPO
The IPO Window: Biotech Keeps Pricing, Tech Still Waits
Small biotech IPOs keep clearing the market while bigger, capital-intensive listings stall: City Therapeutics, TRexBio and Iambic all moved this week while Firmus's $31 billion listing sits withdrawn.
BY THE NUMBERS
TRexBio Closes $116.7M IPO, Lilly Eyes Bigger Stake
IPO$116.7M IPO
TRexBio Closes $116.7M IPO, Lilly Eyes Bigger Stake
TRexBio closed its IPO on Oct. 13, selling 8.33 million shares at $14 for about $116.7 million, with largest shareholder Eli Lilly signaling interest in raising its stake.
DEEP DIVE
Value Add Research
Related Companies
Sources & methodologyshow
Where these figures come from
- FinancialContentresearch database1 fact
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.